Your browser doesn't support javascript.
loading
REducing INFectiOns thRough Cardiac device Envelope: insight from real world data. The REINFORCE project.
Ziacchi, Matteo; Biffi, Mauro; Iacopino, Saverio; di Silvestro, Michele; Marchese, Procolo; Miscio, Francesca; Caccavo, Vincenzo Paolo; Zanotto, Gabriele; Tomasi, Luca; Dello Russo, Antonio; Donazzan, Luca; Boriani, Giuseppe.
Affiliation
  • Ziacchi M; Institute of Cardiology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Via Massarenti 9, 40125 Bologna, Italy.
  • Biffi M; Institute of Cardiology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Via Massarenti 9, 40125 Bologna, Italy.
  • Iacopino S; GVM, Maria Cecilia Hospital, Cotignola.
  • di Silvestro M; Umberto I, Enna.
  • Marchese P; Presidio ospedaliero G. Mazzoni, Ascoli Piceno.
  • Miscio F; Ospedale 'Teresa Masselli Mascia', San Severo, Foggia.
  • Caccavo VP; Ospedale F. Miulli, Acqua Viva delle Fonti.
  • Zanotto G; Ospedale Mater Salutis di Legnago.
  • Tomasi L; Azienda Ospedaliero-Universitaria di Verona.
  • Dello Russo A; Azienda Ospedaliero Universitaria delle Marche, Ancona.
  • Donazzan L; Cardiology Department, Ospedale San Maurizio, Bolzano, Italy.
  • Boriani G; Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
Europace ; 25(11)2023 11 02.
Article in En | MEDLINE | ID: mdl-37490930
AIMS: Infections resulting from cardiac implantable electronic device (CIED) implantation are severely impacting on patients' and on health care systems. The use of TYRXTM absorbable antibiotic-eluting envelope has proven to decrease major CIED infections within 12 months of CIED surgery. The aim is to evaluate the impact of the envelope use on infection-related clinical events in a real-world contemporary patient population. METHODS AND RESULTS: Data on patients undergoing CIED surgery were collected prospectively by participating centers of the One Hospital ClinicalService project. Patients were divided into two groups according to whether TYRXTM absorbable antibiotic-eluting envelope was used or not. Out of 1819 patients, 872 (47.9%) were implanted with an absorbable antibiotic-eluting envelope and included in the Envelope group and 947 (52.1%) patients who did not receive an envelope were included in the Control group. Compared to control, patients in the Envelope group had higher thrombo-embolic or hemorrhagic risk, higher BMI, lower LVEF and more comorbidities. During a mean follow-up of 1.4 years, the incidence of infection-related events was significantly higher in the control compared to the Envelope group (2.4% vs. 0.8%, P = 0.007). The five-year cumulative incidence of infection-related events was 8.1% in the control and 2.1% in the Envelope group (HR: 0.34, 95%CI: 0.14-0.80, P = 0.010). CONCLUSION: In our analysis, the use of an absorbable antibiotic-eluting envelope in the general CIED population was associated with a lower risk of systemic and pocket infection.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Pacemaker, Artificial / Prosthesis-Related Infections / Defibrillators, Implantable / Heart Diseases Limits: Humans Language: En Journal: Europace Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Pacemaker, Artificial / Prosthesis-Related Infections / Defibrillators, Implantable / Heart Diseases Limits: Humans Language: En Journal: Europace Year: 2023 Document type: Article